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Agrin, a synapse-organizing protein externalized by motor axons at the neuromuscular junction (NMJ), initiates a signaling cascade in
muscle cells leading to aggregation of postsynaptic proteins, including acetylcholine receptors (AChRs). We examined whether nitric oxide
synthase (NOS) activity is required for agrin-induced aggregation of postsynaptic AChRs at the embryonic NMJ in vivo and in cultured
muscle cells. Inhibition of NOS reduced AChR aggregation at embryonic Xenopus NMJs by 50–90%, whereas overexpression of NOS
increased AChR aggregate area 2- to 3-fold at these synapses. NOS inhibitors completely blocked agrin-induced AChR aggregation in
cultured embryonic muscle cells. Application of NO donors to muscle cells induced AChR clustering in the absence of agrin. Our results
indicate that NOS activity is necessary for postsynaptic differentiation of embryonic NMJs and that NOS is a likely participant in the agrin-
MuSK signaling pathway of skeletal muscle cells.
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nase (MuSK), which is part of an agrin receptor complex inIntroduction
The formation of the neuromuscular junction involves
the differentiation of both the postsynaptic apparatus of the
muscle cell and the presynaptic nerve terminal, resulting in a
functional synapse. The process begins with motor axon-
muscle cell contact, leading to the aggregation of a complex
of proteins, including acetylcholine receptors (AChRs), in
the postsynaptic membrane opposite the nerve terminal
(Anderson and Cohen, 1977; Frank and Fischbach, 1979).
The neuronal signal for postsynaptic AChR aggregation is
agrin (Godfrey et al., 1984; Nitkin et al., 1987), a heparan
sulfate proteoglycan (Denzer et al., 1995; Tsen et al., 1995)
released by motor nerve terminals that becomes associated
with the synaptic basal lamina (Cohen and Godfrey, 1992;
McMahan, 1990; Reist et al., 1992). Agrin induces rapid
phosphorylation of a muscle-specific receptor tyrosine ki-0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: godfreew@evms.edu (E.W. Godfrey).the postsynaptic membrane (Glass et al., 1996; Valenzuela
et al., 1995). The activation of MuSK is essential for agrin-
induced clustering of AChRs as well as AChR phosphory-
lation (Glass et al., 1997; Zhou et al., 1999). Several other
proteins are essential for AChR aggregation. Rapsyn, a
protein associated with cytoplasmic domains of the AChR,
is thought to link AChRs to the cytoskeleton (Burden et al.,
1983); mice deficient in rapsyn do not form postsynaptic
AChR aggregates (Gautam et al., 1995). However, the steps
in agrin signaling between MuSK activation and cytoske-
letal anchoring of AChRs via rapsyn are poorly understood.
Recent studies indicate that nitric oxide (NO) produced
by nitric oxide synthase (NOS) contributes to the agrin
signaling cascade. NO is a free radical gas (Dawson and
Snyder, 1994) synthesized by three different isoforms of
nitric oxide synthase (NOS): ‘neuronal’ NOS (nNOS or
NOS1), ‘inducible’ NOS (iNOS or NOS2), and ‘endothe-
lial’ NOS (eNOS or NOS3). All three isoforms are present
in adult skeletal muscle fibers (Stamler and Meissner, 2001)
and in fetal mouse muscle (Blottner and Lu¨ck, 1998). NO
diffuses within cells and across membranes to mediate intra-
and intercellular effects, often through the activation of
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subsequently, cGMP-dependent protein kinase (PKG; Tray-
lor and Sharma, 1992). Both NOS1 and NOS2 are localized
to the postsynaptic apparatus of the NMJ, as is PKG
(Askanas et al., 1998; Chao et al., 1997; Kramarcy and
Sealock, 2000; Yang et al., 1997). Agrin causes co-aggre-
gation of NOS1 and AChRs in cultured myotubes (Lu¨ck et
al., 2000). Inhibition of NOS blocked agrin-induced phos-
phorylation and clustering of AChRs in cultured myotubes,
whereas NO donors induced AChR phosphorylation and
clustering (Jones and Werle, 2000). In this study, we show
that NOS activity of muscle cells is necessary for postsyn-
aptic differentiation of the embryonic NMJ. Our results
suggest that NOS is a participant in agrin signal transduction
at this embryonic synapse.Materials and methods
cDNAs; RNA synthesis
The cDNA encoding jellyfish green fluorescent protein
(GFP; S65T mutant) was obtained from Dr. Richard Dorsky
(University of California, San Diego, CA). Rat NOS1
cDNA (Bredt et al., 1991b) was a kind gift of Dr. Bonnie
Firestein, Rutgers University; mouse NOS2 cDNA (Low-
enstein et al., 1992) from Dr. Charles Lowenstein, Johns
Hopkins University; and bovine NOS3 cDNA (Sessa et al.,
1992) from Dr. William Sessa, Yale University. Constructs
encoding enzymatically inactive, truncated NOS1 fragments
(Hallmark et al., 1999; Phung and Black, 1999) were
obtained from Dr. Stephen Black, Northwestern University,
and inactive NOS2 mutants were designed as described by
Xie et al. (1994). Protein coding sequences of all cDNAs
were amplified by PCR. The sense primers contained the
SP6 RNA polymerase promoter and the 5V untranslated
sequence from Xenopus beta globin found in the pCS2
vector (Godfrey et al., 2000; Rupp et al., 1994). RNA was
synthesized using SP6 RNA polymerase and the mMessage
mMachine kit (Ambion; Godfrey et al., 1999).
RNA injection
Embryos of Xenopus laevis were obtained by in vitro
fertilization (Moon and Christian, 1989) and injected with
synthetic RNAs at the one-cell stage using a Nanoject II
injector (Drummond) fitted with glass micropipets (20 Am
diameter tip). Embryos were injected (Moon and Christian,
1989) with 4.6–9.2 nl nuclease-free water containing GFP
RNA (1–2 ng) alone or combined with each of the NOS
RNAs (8–12 ng).
Screening, fixation, and labeling acetylcholine receptors
Following injection of RNAs, embryos were trans-
ferred into 0.1 modified Barth’s saline (MBS; Gurdonand Wickens, 1983), kept at room temperature until 26
h of development (stage 24; Nieuwkoop and Faber,
1994), then incubated overnight at 16–18jC. At stage
31, after NMJs had formed, embryos were screened for
GFP fluorescence. Normal embryos with fluorescence in
the trunk myotomes were fixed in 4% paraformaldehyde
in a sucrose-containing buffer (Lu et al., 1996) for 1
h at 4jC and rinsed in 1 MBS multiple times (2–3
h) until the skin sloughed off. AChRs were labeled
overnight at 4jC with Alexa 594-a-bungarotoxin (1.5
Ag/ml; Molecular Probes) in 1% goat serum in MBS.
Embryos were then washed five times for 15 min in
this solution without toxin, incubated 1–2 h in mount-
ing medium (Valnes and Brandtzaeg, 1985) and
mounted on slides.
Confocal microscopy and image analysis
AChR aggregates were imaged using a confocal
microscope (Olympus Fluoview 100 or Zeiss LSM
510). Images were taken from the fifth through the
seventh myotomes. Six different Z series of four optical
sections (at 1-Am intervals) were acquired from three to
six embryos in each condition. Confocal images were
taken with the same microscope settings for all groups of
embryos within an experiment to ensure comparability of
images. The area of AChR aggregates was measured
with Metamorph image analysis software (Universal
Imaging Corp.). Threshold was set to mark aggregates
in each series of images, and aggregate area was con-
verted to a percentage of the total area of the images.
Statistics were calculated as described (Godfrey et al.,
1999).
Inhibition of NOS in embryos
Embryos were exposed to NOS inhibitors and NO
donors from 26 h of development (stage 24) to stage 31
overnight at 16–18jC. Reagents (Calbiochem) were
dissolved in 1 MBS, except that 7-nitroindazole (7-
NI) was dissolved in DMSO and diluted in MBS.
Controls for 7-NI included 0.8–1.7% DMSO. In some
cases, penetration of inhibitors was facilitated by remov-
ing the skin overlying the trunk myotomes, and inhib-
itors were dissolved in cell culture medium. AChR
aggregates were labeled and quantitated as described
above.
Cell culture studies
Myotomal muscles were removed from stage 20 to
stage 21 embryos. Muscle cells were dissociated and
cultured (Peng et al., 1991) in slide culture wells (NUNC)
coated with E.C.L. (Upstate Biotechnology). Cells (1000–
2000/well) were cultured in 200 Al/well of medium (67%
L-15, 32% Steinberg’s solution [Peng, 1991], 1% fetal
Fig. 1. NOS inhibitors reduce AChR aggregation in vivo. Embryos were
exposed to NOS inhibitors from 26 h of development (stage 24), when
innervation of the myotomes of interest (5–7) had not yet begun, until
38 h (stage 31), when rows of functional synapses have formed between
myotomes. Application of the NOS inhibitors 7-nitroindazole (7-NI, 0.5
mM; B), vinyl-L-NIO (5 mM, C) and 1400W (4 mM, D) resulted in 77, 99,
and 89% reductions in AChR aggregate area, respectively, at embryonic
NMJs, compared to untreated control embryos (A). Scale bar, 20 Am.
Table 1
NOS inhibitors reduce endogenous AChR aggregation at the embryonic
neuromuscular junction
Experiment
no.
Inhibitor AChR
aggregate area
(% F SEM)
Inhibition
(%)
P vs.
Control
1 Control 0.075 F 0.035 – –
7-NI (0.5 mM) 0.0067 F 0.003 91 0.031
2 Control 0.27 F 0.046 – –
7-NI (0.5 mM) 0.062 F 0.024 77 0.00081
3 Control 0.238 F 0.087 – –
1400W (4 mM) 0.026 F 0.0092 89 0.006
4 Control 0.76 F 0.2 – –
1400W (1 mM) 0.23 F 0.054 70 0.011
5 Control (skinned) 0.33 F 0.082 –
Vinyl-L-NIO
(5 mM)
0.0033 F 0.0021 99 0.0002
Embryos were exposed to inhibitors from stage 24 (26 h of development) to
stage 31 (38 h), a period in which neuromuscular junctions form in
myotomal muscles. AChRs were labeled and images were collected from
six myotomes; average values of aggregate area are shown. With
7-nitroindazole (7-NI; 0.5–1 mM), AChR aggregate area was inhibited
an average of 70% (n = 7 experiments; range 37–91%), whereas 1400W
(1–8 mM) inhibited an average of 65% (n = 6 experiments; range 48–
89%); in three experiments, skin overlying trunk muscles was removed.
Application of 7-NI (0.5–1 mM) included 0.8–1.7% DMSO (also in
controls), and six of seven experiments were done with intact embryos (in
one experiment, skin was removed from trunk myotomes at stage 24).
Vinyl-L-NIO (1–5 mM; Babu and Griffith, 1998) resulted in an average of
81% inhibition (n = 4 experiments; range 35–99%); skin overlying trunk
muscles was removed.
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for experiments after 1–3 days, when the cells had
attached and spread. NOS inhibitors were added 2 h before
3–5 ng/ml agrin (half-maximal dose) and inhibitor for 14
h. NO donors were added to cultures without agrin but for
the same period. After 16–18 h at 22jC, cells were fixed
in 4% paraformaldehyde and AChRs were labeled with
Alexa 594-a-bungarotoxin. Aggregates of AChRs (>1 Am)
were counted in each of 20 cells per well in duplicate
wells for each condition.
NADPH-diaphorase histochemistry and NOS activity assay
Embryos at 38 h of development (stage 31) were fixed
for 2 h in ice-cold 4% paraformaldehyde, rinsed in 1
MMR (Marc’s modified Ringer; Peng, 1991), placed in
30% sucrose overnight at 4jC, embedded, and frozen in
sucrose-based medium (Fisher Scientific). Frozen sections
were mounted on poly-L-lysine-coated slides and dried
for 1 h at 37jC. Sections were treated 3 min with 0.3%
Triton X-100 and incubated 1–3 h at 37jC in reaction
medium (McLean and Sillar, 2000) in a humid chamber.
Reagents were from Sigma. The reaction was stopped by
rinsing sections in 1 MMR and slides were mounted in
glycerol.
To determine the IC50 values of 7-NI and 1400W for
Xenopus NOS1, homogenates of adult Xenopus brainswere treated with various concentrations of inhibitors
before and during assay of NOS enzymatic activity using
a modification of the method of Bredt and Snyder
(1989). This method was also used to quantitate the
increase in NOS activity in 24–26 h (stage 22–24)
and 38 h (stage 31) embryos injected with NOS or
GFP (control) RNAs.Results
NOS inhibitors reduce AChR aggregation at the embryonic
neuromuscular junction and completely block
agrin-induced AChR aggregation in
isolated myotomal muscle cells
To indicate whether NOS activity is required for post-
synaptic differentiation during formation of the embryonic
NMJ, we determined whether NOS inhibitors affected
AChR aggregation at NMJs in developing Xenopus em-
bryos. Embryos were exposed to the inhibitors from stage
24, when innervation of the myotomes of interest had not
yet begun, until stage 31, when rows of functional synap-
ses had formed. The NOS inhibitors 7-nitroindazole (7-
NI), vinyl-L-NIO, and 1400W reduced AChR aggregate
area by up to 77%, 99%, and 89%, respectively (Figs.
1A–D). Each experiment was performed 3–7 times,
resulting in average inhibition of 65–81% with these
Fig. 2. Isoform-selective NOS inhibitors completely block agrin-induced
AChR aggregation in cultured Xenopus embryo myotomal muscle cells.
Cells were pre-treated with NOS inhibitors 2 h before 14 h incubation with
agrin (half-maximal dose of 3–5 ng/ml) and NOS inhibitor. AChR
aggregates (white) were then labeled with fluorescent a-bungarotoxin.
Treatment with agrin and the NOS inhibitors 7-NI (200 AM, C) and 1400W
(1 AM; D, image from cells treated with 0.1 AM 1400W) reduced AChR
aggregation to background levels observed in the untreated control (A),
which was significantly lower than agrin (B) treatment alone.
Table 2
NOS overexpression increases AChR aggregation in embryos
RNA injected (ng) AChR aggregate
area (% F SEM)
Area ratio
NOS/GFP
P vs. GFP
Control
GFP (1) 0.77 F 0.14 – –
nNOS (6) F GFP (1) 1.56 F 0.38 2.0 0.05
iNOS (10)F GFP (1) 2.54 F 0.27 3.3 7  105
eNOS (6) F GFP (1) 1.85 F 0.32 2.4 0.005
Data are from the experiment shown in Fig. 4. Averages (FSEM) of AChR
aggregate area from six stacks of images per group are shown.
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aggregate area, embryos treated with inhibitors appeared to
develop normally, including the appearance of the myoto-
mal muscles.
To confirm that the NOS inhibitors blocked postsyn-
aptic differentiation via a cell-autonomous effect on
muscle cells, we isolated and cultured myotomal muscle
cells before innervation (from stage 20 to stage 22
embryos), and determined the effects of 7-NI and
1400W on agrin-induced clustering of AChRs. Treatment
of muscle cells with these inhibitors completely blocked
agrin-induced AChR aggregation (Fig. 2). The IC50
values for inhibition were approximately 1 nM and 25
AM for 1400W and 7-NI, respectively (Figs. 3A, B).
Addition of the NOS substrate L-arginine (2 mM) to the
culture medium completely reversed blocking of agrin
activity by 7-NI (data not shown), indicating that 7-NI
interference with agrin activity was caused by inhibition
of NOS activity rather than non-specific effects such as
toxicity.
Since the effects of these inhibitors on NOS isoforms in
Xenopus had not been characterized, we determined the
concentration of inhibitors necessary to block the activity
of NOS in homogenates of adult Xenopus brain (predom-
inantly NOS1; Huang et al., 1993). Attempts to obtain
sufficient NOS2 activity for similar studies from activated
macrophages of adult frogs were unsuccessful. The IC50
values for inhibition of NOS activity in Xenopus brain
homogenates were approximately 15 and 0.2 AM for
1400W and 7-nitroindazole, respectively (data not shown).These values are four orders of magnitude higher and two
orders of magnitude lower, respectively, than the IC50
values we obtained for agrin-induced AChR aggregation
in Xenopus embryo muscle cells. Thus, agrin signaling in
muscle cells may involve activity of a NOS isoform or
splice variant with different inhibitor characteristics than
the NOS1 in brain.
Overexpression of NOS increases AChR aggregation at the
embryonic NMJ
To further investigate the importance of NOS in post-
synaptic differentiation of the embryonic NMJ, we over-
expressed each of the NOS isoforms by RNA injection.
RNA encoding NOS1, NOS2, or NOS3 was injected into
one-cell Xenopus embryos, resulting in a 100–200%
increase in synaptic AChR aggregate area at stage 31 over
controls injected with GFP RNA (Fig. 4; Table 2). Devel-
opment of these embryos appeared normal compared to
controls.
To confirm that increased AChR aggregation in em-
bryos injected with NOS RNA was a result of increased
NOS enzymatic activity, we assayed activity in injected
embryos at stages 22–23 and 31. Injection of NOS1 or
NOS2 RNA into one-cell Xenopus embryos resulted in
NOS enzymatic activity 2- to 5-fold greater than control
levels at stages 22–23, when NMJs are beginning to
form, and 0–80% greater than controls at stage 31, when
AChR aggregation at NMJs was routinely assayed (data
not shown). Expression of truncated inactive NOS1 and
NOS2 proteins did not increase AChR aggregation in
muscles, indicating that enzymatically active NOS is
required.
NO donors increase AChR aggregation in embryonic
muscle cells
The ability of NOS inhibitors to block agrin activity in
muscle cells indicates that NOS activity is necessary for
agrin signaling in these cells. We tested whether increased
NO was also sufficient for AChR aggregation by adding
the NO donors SNP or SNAP to the culture medium of
embryonic muscle cells. Both NO donors significantly
increased the number of AChR aggregates in these cells
(Table 3), although the increases (to 1.5- to 2.4-fold
Fig. 3. Isoform-selective NOS inhibitors reduce the number of agrin-induced
AChR aggregates in cultured Xenopus embryo myotomal muscle cells.
AChRs were labeled with fluorescent a-bungarotoxin and aggregatesz1 Am
in diameter were counted in 20–40 cells per condition. The percentage of
agrin-induced AChR aggregates remaining with inhibitor treatment is shown.
Error bars indicate the range of data from two different wells of cells. The
NOS inhibitors 7-nitroindazole (7-NI, A) and 1400W (B) reduced agrin-
induced aggregation of AChRs in a dose-dependent manner with IC50 values
of approximately 25 AM and 1 nM, respectively, consistent with published
IC50 values for NOS2.
Fig. 4. Overexpression of NOS increases AChR aggregation in embryonic
muscles. RNA encoding nNOS (B; 6 ng), iNOS (C; 10 ng), and eNOS (D; 6
ng) was injected into fertilized Xenopus embryos at the one-cell stage.
Overexpression of each of the NOS isoforms resulted in a significant increase
in synaptic AChR aggregate area at 38 h of development over controls
injected with GFP RNA (A; 1 ng). AChR aggregate area (A, 0.36%; B, 2.0%;
C, 2.9%; D, 1.6%) was quantitated by confocal microscopy and image
analysis after labeling with fluorescent a-bungarotoxin. Projected stacks of
four serial sections taken at 1 Am intervals are shown. Scale bar, 20 Am.
Table 3
Nitric oxide donors induce AChR aggregation in Xenopus embryo muscle
cell cultures
Treatment AChR
aggregates/cell
Ratio
donor/control
P vs. Control
Control 3.6 F 0.48 – –
SNP (0.02 mM) 5.4 F 0.85 1.5 5  105
SNAP (0.1 mM) 5.6 F 0.85 1.5 4  105
Control 2.3 F 0.48 – –
SNP (0.1 mM) 3.4 F 0.96 1.5 0.02
SNAP (0.5 mM) 5.5 F 0.85 2.4 9  1010
Cultures of Xenopus embryo muscle cells were treated 16 h with NO donors
(SNP: sodium nitroprusside; SNAP: S-nitroso-N-acetylpenicillamine).
AchR aggregates were labeled with fluorescent a-bungarotoxin; aggregates
>1 Am in diameter were counted in 40 cells.
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agrin (3- to 6-fold with a maximal dose).
NOS activity is concentrated in innervated regions of
embryonic muscles
The activity of NOS was localized to the innervated
regions of embryonic myotomal muscles using the histo-
chemical assay for NADPH-diaphorase. In fixed tissue, this
assay is specific for NOS activity (Bredt et al., 1991a;
Descarries et al., 1998; Matsumoto et al., 1993). Reaction
product was concentrated in the distal portions of embryonic
muscle cells, adjacent to sites of innervation (Fig. 5).
Diaphorase histochemical activity in myotomal muscles
was inhibited by the NOS inhibitor L-NNA (1 mM; data
not shown). These results indicate that, as in the mammalian
NMJ, NOS activity is localized to postsynaptic portions of
frog embryo muscle cells, consistent with NOS being a
mediator of agrin signaling during development of this
synapse.Discussion
NOS is a likely mediator of agrin signaling at the embryonic
NMJ
We analyzed the role of NOS activity in AChR aggre-
gation at the embryonic NMJ. Our results indicate that NOS
is likely to be a mediator of agrin signaling leading to
postsynaptic AChR aggregation during synaptogenesis, be-
cause NOS activity is necessary and may also be sufficient
for agrin signaling at the embryonic NMJ.
Fig. 5. Localization of NOS activity in myotomal muscle using the
NADPH-diaphorase histochemical assay. The reaction product was
concentrated at the ends of the myotomes (arrow), where innervation by
motor axons occurs. Scale bar, 20 Am.
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7-nitroindazole, vinyl-L-NIO and 1400W greatly inhibited
AChR aggregation at embryonic NMJs. Much higher
concentrations of inhibitors were necessary to block AChR
aggregation in vivo than in culture, which may reflect
impaired penetration of these compounds into embryonic
muscles. Nevertheless, NOS inhibitors reduced AChR
aggregation in embryos 50–90%, suggesting that NOS
activity is necessary for agrin-induced differentiation of the
postsynaptic apparatus. Both 7-NI and 1400W completely
blocked agrin-induced AChR clustering in cultured muscle
cells. The IC50 values of these inhibitors in the culture
experiments (1 nM for 1400W; 25 AM for 7-NI) were
similar to those reported for mammalian NOS2 (iNOS)
rather than for NOS1 or NOS3 (Garvey et al., 1997; Wolff
and Gribin, 1994). The concentrations of these inhibitors
necessary to inhibit 50% of NOS activity in Xenopus brain
homogenates (mostly NOS1; Huang et al., 1993) were
similar to IC50 values for mammalian NOS1 (Garvey
et al., 1997; Wolff and Gribin, 1994). Although we did
not obtain sufficient NOS2 activity from frog macrophages
to measure its response to inhibitors, the IC50 values
obtained with Xenopus brain NOS suggest that a NOS
isoform or variant other than the NOS1 found in brain
plays a role in agrin signaling in Xenopus embryo muscle
cells. Like NOS1, NOS2 is also localized at the mamma-
lian NMJ (Yang et al., 1997), but unlike NOS1, the
mechanisms by which NOS2 targeting and activity are
regulated at the NMJ are unknown. However, NOS2 is
expressed in muscle cells early in myogenesis and is
required for myoblast fusion (Kaliman et al., 1999).
Because NOS2 sequence is not yet available in Xenopus,
we do not know if this isoform is expressed in myotomal
muscles during NMJ formation.
Alternatively, our results with NOS inhibitors could
indicate that splice variants of NOS1 in muscle cells
participate in agrin signaling. Multiple splice variants of
NOS1 are present in mammalian brain and other organs
(Brenman et al., 1997; Eliasson et al., 1997), and aunique variant (nNOS-A) is found in mammalian skeletal
muscle cells (Silvagno et al., 1996). The sequence of X.
laevis NOS1 cDNA has been determined (Peunova et al.,
2001), and a complex set of alternatively spliced variants
is found in embryos, including their muscles (N. Peunova
and V. Scheinker, personal communication). Although the
inhibitor characteristics of NOS activity from Xenopus
brain (predominantly NOS1) did not match those of
agrin-induced AChR aggregation in muscle cells, spice
variants of NOS1 expressed in muscle cells could have
inhibitor characteristics like those of NOS2 and may
participate in agrin signaling at the embryonic NMJ.
Consistent with the possible involvement of NOS1 in
agrin signaling, we have recently found by RT-PCR that
NOS1 is expressed in stage 24 muscles, in which NMJs
are just beginning to form (E. Orlova and E.W. Godfrey,
unpublished results).
The NO donors SNAP and SNP induced significant
increases in AChR aggregation in cultured Xenopus embryo
muscle cells in the absence of agrin, as was also found in
chick myotubes (Jones and Werle, 2000). However, in
Xenopus muscle cells, NO donors increased AChR aggre-
gates to a lesser extent than agrin. These donors release NO,
but agrin could stimulate nitric oxide synthases to produce,
in addition to NO, other reactive nitrogen species (RNS)
such as peroxynitrite (Alderton et al., 2001). Peroxynitrite,
like NO, can activate src kinases (Akhand et al., 1999;
Mallozzi et al., 1999), which could facilitate AChR aggre-
gation (Willman and Fuhrer, 2002).
Overexpression of each of the three NOS isoforms
resulted in a significant increase in AChR aggregation at
developing Xenopus NMJs. These results probably reflect
increased stimulation of signaling pathways by NO pro-
duced by the additional enzyme, rather than a non-specific
effect, since embryonic development did not appear to be
aberrant. Although NOS2 and NOS3 lack the PDZ domain
by which NOS1 associates with a-syntrophin at the NMJ
(Alderton et al., 2001), diffuse cytoplasmic NOS2 or
NOS3 apparently still stimulated the normal signaling
pathway, leading to AChR aggregation. The ability of all
three NOS isoforms to increase AChR aggregation in
embryonic muscles indicates that NO stimulates at least a
portion of the agrin signal transduction pathway in muscle
cells.
Taken together, our results indicate that NO produced
by NOS is necessary and may be sufficient for agrin-
induced aggregation of AChRs in cultured myotomal
muscle cells, and suggest that NO production may also
be necessary for nerve-induced AChR aggregation at the
embryonic NMJ. Although our data support the hypoth-
esis that NOS mediates agrin signaling, we cannot rule
out the possibility that NO is a modulator of the agrin
signal transduction network. It will be necessary to obtain
more direct evidence demonstrating that agrin regulates
NOS activity before this issue can be conclusively
resolved.
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Our results may appear to contradict the finding that in
NOS1 null mice, the NMJs function normally (Huang
et al., 1993). However, brains of these NOS1 null mice,
generated by the deletion of exon 2, exhibit 5% residual
NOS activity due to expression of two NOS1 splice
variants lacking this exon (Eliasson et al., 1997). These
or other splice variants could also be present in muscle
cells of NOS1 null mice, accounting in part for the
apparently normal morphology of their NMJs (Shiao et
al., 2004), which could be organized by agrin through the
residual NOS1 or NOS2 activity. However, AChR density
at NMJs of NOS1 null mice is reduced about 50%
compared to controls, and in transgenic mice that over-
express NOS1, AChR density is 30% greater than in
control mice (Shiao et al., 2004). These results are
consistent with our findings indicating an important role
for NOS in AChR aggregation at the NMJ. Interpretation
of results from NOS null mice is further complicated by
the fact that NOS isoforms can compensate for one
another (Burnett et al., 1996; Eliasson et al., 1997; Son
et al., 1996; Wang et al., 1999). Our finding that over-
expression of each of the three NOS isoforms resulted in a
significant increase in AChR aggregation in developing
Xenopus muscles may reflect this compensatory phenom-
enon.
Potential mechanisms downstream of NOS activation in
agrin signaling
Our findings are consistent with the idea that an increase
in NO production is part of the agrin/MuSK signal trans-
duction pathway. However, the mechanism of NOS activa-
tion and the subsequent steps leading to aggregation of
AChRs and other postsynaptic proteins are unclear. In a
recent review article (Godfrey and Schwarte, 2003), we
have outlined several possible signaling mechanisms both
upstream and downstream of NOS that could mediate agrin
activity in muscle cells.
The effects of NO on AChR aggregation are likely be
mediated, at least in part, by stimulation of a typical NO
effector, soluble guanylate cyclase (sGC). This enzyme is
stimulated by NO to increase its synthesis of cyclic GMP,
activating cGMP-dependent protein kinase (PKG; Hoff-
mann et al., 2000; Stone et al., 1995). Like NOS, both
sGC and PKG are concentrated postsynaptically at the
NMJ (Chao et al., 1997; Schoser and Behrends, 2001). A
cGMP analog, 8-bromo-cGMP, which stimulates PKG,
increased AChR aggregate area at embryonic Xenopus
NMJs by 100–200% (Godfrey et al., 2003), similar to its
effect on aggregation in chick muscle cells (Jones and
Werle, 2004). Furthermore, overexpression of sGC and
PKG in Xenopus embryos increased AChR aggregation
to a similar extent as overexpression of agrin and NOS
R.C. Schwarte, E.W. Godfrey / Dev282(Godfrey et al., 2003). It is unclear how sGC and PKG
might interact with other components involved in agrin
signal transduction, but defining the protein targets of PKG
phosphorylation might reveal connections with other mole-
cules known to be involved in postsynaptic differentiation.Acknowledgments
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